Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD

Sodium glucose cotransporter‐2 inhibitors (SGLT2is) are now widely used to treat diabetes, but their effects on nonalcoholic fatty liver disease (NAFLD) remain to be determined. We aimed to evaluate the effects of SGLT2is on the pathogenesis of NAFLD. A multicenter, randomized, controlled trial was...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Hirokazu, Kessoku, Takaomi, Kawanaka, Miwa, Nonaka, Michihiro, Hyogo, Hideyuki, Fujii, Hideki, Nakajima, Tomoaki, Imajo, Kento, Tanaka, Kenichi, Kubotsu, Yoshihito, Isoda, Hiroshi, Oeda, Satoshi, Kurai, Osamu, Yoneda, Masato, Ono, Masafumi, Kitajima, Yoichiro, Tajiri, Ryo, Takamori, Ayako, Kawaguchi, Atsushi, Aishima, Shinichi, Kage, Masayoshi, Nakajima, Atsushi, Eguchi, Yuichiro, Anzai, Keizo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710792/
https://www.ncbi.nlm.nih.gov/pubmed/34558835
http://dx.doi.org/10.1002/hep4.1696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710792/
https://www.ncbi.nlm.nih.gov/pubmed/34558835
http://dx.doi.org/10.1002/hep4.1696

Ejemplares similares